Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1191

1.

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS.

J Gen Intern Med. 2019 Jul 16. doi: 10.1007/s11606-019-05149-6. [Epub ahead of print] No abstract available.

PMID:
31313117
2.

The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry.

Pendyal A, Ross JS.

JAMA. 2019 Jul 16;322(3):190-192. doi: 10.1001/jama.2019.8147. No abstract available.

PMID:
31310276
3.

Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.

Zhang AD, Schwartz JL, Ross JS.

Milbank Q. 2019 Jul 14. doi: 10.1111/1468-0009.12403. [Epub ahead of print]

PMID:
31304643
4.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
6.

Clinical Trial Evidence for the Real World.

Ross JS, Covinsky K.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1500. [Epub ahead of print] No abstract available.

PMID:
31282933
7.

Association Between Industry Payments to Physicians and Gabapentinoid Prescribing.

Rhee TG, Ross JS.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1082. [Epub ahead of print] No abstract available.

PMID:
31282922
8.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

9.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
10.

Clinical and immunological implications of frameshift mutations in lung cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496-4. doi: 10.1016/j.jtho.2019.06.016. [Epub ahead of print]

PMID:
31238177
11.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

12.

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS.

BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.

13.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Jun 12. doi: 10.1038/s41379-019-0303-z. [Epub ahead of print]

PMID:
31190001
14.

Non-Inferiority Designed Cardiovascular Trials in Highest-Impact Journals: Main Findings, Methodological Quality and Time Trends.

Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone GW, Ross JS, Krumholz HM.

Circulation. 2019 Jun 10. doi: 10.1161/CIRCULATIONAHA.119.040214. [Epub ahead of print]

PMID:
31177811
15.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30149-X. doi: 10.1016/j.euf.2019.05.012. [Epub ahead of print]

PMID:
31147264
16.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.

Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL.

J Am Geriatr Soc. 2019 May 29. doi: 10.1111/jgs.15966. [Epub ahead of print]

PMID:
31140587
17.

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.

Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD.

JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.

18.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
19.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Apr 30. pii: mdz134. doi: 10.1093/annonc/mdz134. [Epub ahead of print]

PMID:
31038663
20.

Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.

Fleischman W, Agrawal S, Gross CP, Ross JS.

J Gen Intern Med. 2019 Jul;34(7):1074-1076. doi: 10.1007/s11606-019-04897-9. No abstract available.

PMID:
31011967
21.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
22.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults [Internet].

Sobieraj DM, Baker WL, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Mar.

23.

Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study.

Weerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI.

J Am Med Dir Assoc. 2019 Apr;20(4):432-437. doi: 10.1016/j.jamda.2019.01.135.

PMID:
30954133
24.

Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition.

Venkatesh AK, Chou SC, Li SX, Choi J, Ross JS, D'Onofrio G, Krumholz HM, Dharmarajan K.

JAMA Intern Med. 2019 Apr 1. doi: 10.1001/jamainternmed.2019.0037. [Epub ahead of print]

PMID:
30933243
25.

Kept in the dark: Scotland rejects "sunshine" legislation.

Ross JS.

BMJ. 2019 Mar 29;364:l1379. doi: 10.1136/bmj.l1379. No abstract available.

PMID:
30926587
26.

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.

Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS.

JAMA Netw Open. 2019 Mar 1;2(3):e191340. doi: 10.1001/jamanetworkopen.2019.1340.

27.

Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation.

Jackevicius CA, An J, Ko DT, Ross JS, Angraal S, Wallach JD, Koh M, Song J, Krumholz HM.

BMJ Open. 2019 Mar 23;9(3):e025936. doi: 10.1136/bmjopen-2018-025936.

28.

U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.

Vijay A, Rhee TG, Ross JS.

Prev Med. 2019 Jun;123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

PMID:
30894321
29.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

30.

Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials.

Ross JS, Wee CC.

JAMA Intern Med. 2019 Mar 4. doi: 10.1001/jamainternmed.2018.8019. [Epub ahead of print] No abstract available.

PMID:
30830205
31.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM.

Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.

PMID:
30796031
32.

On the Need for (Only) High-Quality Clinical Practice Guidelines.

Incze M, Ross JS.

JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7471. [Epub ahead of print] No abstract available.

PMID:
30776052
33.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
34.

Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.

Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2305-2314. doi: 10.1210/jc.2018-02197.

PMID:
30690529
35.

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB.

Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25.

PMID:
30683711
36.

Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.

Necchi A, Bratslavsky G, Chung J, Millis S, Gay LM, Ali SM, Ross JS.

Oncologist. 2019 Apr;24(4):e142-e145. doi: 10.1634/theoncologist.2018-0430. Epub 2019 Jan 18.

PMID:
30659078
37.

Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.

Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, Kasid UN.

Mol Cancer Res. 2019 May;17(5):1207-1219. doi: 10.1158/1541-7786.MCR-18-0731. Epub 2019 Jan 15.

PMID:
30647104
38.

Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation.

Downing NS, Wang C, Gupta A, Wang Y, Nuti SV, Ross JS, Bernheim SM, Lin Z, Normand ST, Krumholz HM.

JAMA Netw Open. 2018 Sep 7;1(5):e182044. doi: 10.1001/jamanetworkopen.2018.2044.

39.

Age of Data at the Time of Publication of Contemporary Clinical Trials.

Welsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, Zimmerman CO, Mu L, Ross JS, Krumholz HM.

JAMA Netw Open. 2018 Aug 3;1(4):e181065. doi: 10.1001/jamanetworkopen.2018.1065.

40.

Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.

Puthumana J, Miller JE, Kim J, Ross JS.

JAMA Netw Open. 2018 Jun 1;1(2):e180283. doi: 10.1001/jamanetworkopen.2018.0283.

41.

Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes.

Chui PW, Parzynski CS, Ross JS, Desai NR, Gurm HS, Spertus JA, Seto AH, Ho V, Curtis JP.

J Am Heart Assoc. 2019 Jan 22;8(2):e010373. doi: 10.1161/JAHA.118.010373.

42.

Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017.

Vijay A, Ross JS, Shah ND, Jeffery MM, Dhruva SS.

J Gen Intern Med. 2019 Apr;34(4):518-520. doi: 10.1007/s11606-018-4752-8. No abstract available.

PMID:
30623386
43.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

PMID:
30609392
44.

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R.

Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24.

45.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

46.

Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.

Wallach JD, Egilman AC, Ross JS, Woloshin S, Schwartz LM.

J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x. No abstract available.

PMID:
30543020
47.

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.

Neilsen BK, Sleightholm R, McComb R, Ramkissoon SH, Ross JS, Corona RJ, Miller VA, Cooke M, Aizenberg MR.

J Neurooncol. 2019 Mar;142(1):111-118. doi: 10.1007/s11060-018-03070-2. Epub 2018 Dec 9.

PMID:
30535594
48.

Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism.

Bikdeli B, Wang Y, Jimenez D, Ross JS, Monreal M, Goldhaber SZ, Krumholz HM.

JAMA Intern Med. 2019 Feb 1;179(2):263-265. doi: 10.1001/jamainternmed.2018.5287. No abstract available. Erratum in: JAMA Intern Med. 2019 May 28;:.

PMID:
30535318
49.

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.

Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, Ross JS, Ali SM.

Oncotarget. 2018 Nov 9;9(88):35809-35812. doi: 10.18632/oncotarget.26260. eCollection 2018 Nov 9.

50.

Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold.

Richman IB, Ross JS.

Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-3066. [Epub ahead of print] No abstract available.

PMID:
30508426

Supplemental Content

Support Center